Literature DB >> 19436828

SHP-2 tyrosine phosphatase in human diseases.

Hong Zheng1, Shawn Alter, Cheng-Kui Qu.   

Abstract

SHP-2, a ubiquitously expressed Src homology 2 (SH2) domain-containing protein tyrosine phosphatase (PTP), plays a critical role in physiology and disease. SHP-2 has been clearly demonstrated to be an important molecule in various cytoplasmic signal transduction pathways. In addition, emerging evidence indicates that SHP-2 may function in the nucleus and in the mitochondria. However, the signaling mechanisms of SHP-2 are not completely understood. Interestingly, genetic mutations in SHP-2 that either enhance or inactivate its catalytic activity have been identified in human diseases with overlapping phenotypes. In light of this hint given by nature, new cell and animal models now provide the opportunity to uncover how this molecule functions in multiple cellular processes, and more importantly, how its known mutations induce human diseases.

Entities:  

Year:  2009        PMID: 19436828      PMCID: PMC2680053     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  64 in total

1.  Tyrosine phosphatase activity in mitochondria: presence of Shp-2 phosphatase in mitochondria.

Authors:  M Salvi; A Stringaro; A M Brunati; E Agostinelli; G Arancia; G Clari; A Toninello
Journal:  Cell Mol Life Sci       Date:  2004-09       Impact factor: 9.261

2.  Crystal structure of the tyrosine phosphatase SHP-2.

Authors:  P Hof; S Pluskey; S Dhe-Paganon; M J Eck; S E Shoelson
Journal:  Cell       Date:  1998-02-20       Impact factor: 41.582

3.  Abnormal mesoderm patterning in mouse embryos mutant for the SH2 tyrosine phosphatase Shp-2.

Authors:  T M Saxton; M Henkemeyer; S Gasca; R Shen; D J Rossi; F Shalaby; G S Feng; T Pawson
Journal:  EMBO J       Date:  1997-05-01       Impact factor: 11.598

4.  Protein-tyrosine-phosphatase SHPTP2 couples platelet-derived growth factor receptor beta to Ras.

Authors:  A M Bennett; T L Tang; S Sugimoto; C T Walsh; B G Neel
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-19       Impact factor: 11.205

Review 5.  Noonan syndrome. An update and review for the primary pediatrician.

Authors:  J A Noonan
Journal:  Clin Pediatr (Phila)       Date:  1994-09       Impact factor: 1.168

6.  Insulin signaling in mice expressing reduced levels of Syp.

Authors:  J M Arrandale; A Gore-Willse; S Rocks; J M Ren; J Zhu; A Davis; J N Livingston; D U Rabin
Journal:  J Biol Chem       Date:  1996-08-30       Impact factor: 5.157

7.  SHP-2 phosphatase is required for hematopoietic cell transformation by Bcr-Abl.

Authors:  Jing Chen; Wen-Mei Yu; Hanako Daino; Hal E Broxmeyer; Brian J Druker; Cheng-Kui Qu
Journal:  Blood       Date:  2006-09-26       Impact factor: 22.113

8.  Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation.

Authors:  Toshiyuki Araki; M Golam Mohi; Fraz A Ismat; Roderick T Bronson; Ifor R Williams; Jeffery L Kutok; Wentian Yang; Lily I Pao; D Gary Gilliland; Jonathan A Epstein; Benjamin G Neel
Journal:  Nat Med       Date:  2004-07-25       Impact factor: 53.440

Review 9.  Oncogenic mechanisms of the Helicobacter pylori CagA protein.

Authors:  Masanori Hatakeyama
Journal:  Nat Rev Cancer       Date:  2004-09       Impact factor: 60.716

10.  A new function for a phosphotyrosine phosphatase: linking GRB2-Sos to a receptor tyrosine kinase.

Authors:  W Li; R Nishimura; A Kashishian; A G Batzer; W J Kim; J A Cooper; J Schlessinger
Journal:  Mol Cell Biol       Date:  1994-01       Impact factor: 4.272

View more
  8 in total

1.  Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3.

Authors:  Fang-Ming Gu; Quan-Lin Li; Qiang Gao; Jia-Hao Jiang; Xiao-Yong Huang; Jin-Feng Pan; Jia Fan; Jian Zhou
Journal:  World J Gastroenterol       Date:  2011-09-14       Impact factor: 5.742

Review 2.  Targeting SHP2 phosphatase in hematological malignancies.

Authors:  Rahul Kanumuri; Santhosh Kumar Pasupuleti; Sarah S Burns; Baskar Ramdas; Reuben Kapur
Journal:  Expert Opin Ther Targets       Date:  2022-05-03       Impact factor: 6.797

3.  Association of polymorphism of PTPN 11 encoding SHP-2 with gastric atrophy but not gastric cancer in Helicobacter pylori seropositive Chinese population.

Authors:  Jing Jiang; Zhi-Fang Jia; Fei Kong; Mei-Shan Jin; Yin-Ping Wang; Suyan Tian; Jian Suo; Xueyuan Cao
Journal:  BMC Gastroenterol       Date:  2012-07-12       Impact factor: 3.067

4.  PLCβ1-SHP-2 complex, PLCβ1 tyrosine dephosphorylation and SHP-2 phosphatase activity: a new part of Angiotensin II signaling?

Authors:  Lorenzo A Calò; Luciana Bordin; Paul A Davis; Elisa Pagnin; Lucia Dal Maso; Gian Paolo Rossi; Achille C Pessina; Giulio Clari
Journal:  J Biomed Sci       Date:  2011-06-13       Impact factor: 8.410

5.  The Shp2-induced epithelial disorganization defect is reversed by HDAC6 inhibition independent of Cdc42.

Authors:  Sui-Chih Tien; Hsiao-Hui Lee; Ya-Chi Yang; Miao-Hsia Lin; Yu-Ju Chen; Zee-Fen Chang
Journal:  Nat Commun       Date:  2016-01-19       Impact factor: 14.919

6.  SHP2 is induced by the HBx-NF-κB pathway and contributes to fibrosis during human early hepatocellular carcinoma development.

Authors:  Hyo Jeong Kang; Dal-Hee Chung; Chang Ohk Sung; Su Hyun Yoo; Eunsil Yu; Nayoung Kim; Sy-Hye Lee; Ji-Young Song; Chong Jai Kim; Jene Choi
Journal:  Oncotarget       Date:  2017-04-18

7.  SHP-2 phosphatase contributes to KRAS-driven intestinal oncogenesis but prevents colitis-associated cancer development.

Authors:  Jessica Gagné-Sansfaçon; Geneviève Coulombe; Marie-Josée Langlois; Ariane Langlois; Marilene Paquet; Julie Carrier; Gen-Sheng Feng; Cheng-Kui Qu; Nathalie Rivard
Journal:  Oncotarget       Date:  2016-10-04

Review 8.  Strategies to overcome drug resistance using SHP2 inhibitors.

Authors:  Meng Liu; Shan Gao; Reham M Elhassan; Xuben Hou; Hao Fang
Journal:  Acta Pharm Sin B       Date:  2021-03-28       Impact factor: 11.413

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.